Earlier studies have shown that tumour CD4+ T-lymphocyte infiltration was associated with poor outcome, independent of grade or stage, in patients with a variety of cancer including renal and prostate cancer (Bromwich et al, 2003; McArdle et al, 2004). This evidence concerns the gene CD4 and prostate cancer.